What does an earnings surprise mean?

An earnings surprise is the difference between a company's reported EPS or revenue and the analysts' consensus estimate. A positive surprise means results exceeded expectations, while a negative surprise means results fell short.

How can earnings reports affect TARS stock?

Earnings reports can increase volatility in TARS stock, especially when reported EPS, revenue or company guidance differs from market expectations. An earnings beat does not always lead to a price increase, as investors also consider the outlook, valuation and broader market conditions.

Tarsus Pharmaceuticals Inc Earnings Dates & Reports

This page offers detailed Tarsus Pharmaceuticals Inc earnings data including the latest Tarsus Pharmaceuticals Inc earnings report, the upcoming Tarsus Pharmaceuticals Inc earnings date, historical data and Tarsus Pharmaceuticals Inc earnings call news.

TARS Latest Quarter’s Earnings

Announce Date8/6/2026

EPS Actual (USD)-0.43

Revenue Actual (USD)173.91M

TARS Upcoming Quarter's Earnings

Announce Date--

EPS Forecast (USD)--

Revenue Forecast (USD)--

TARS FY2025 Earnings

EPS (YoY)-1.5948.27%

Revenue (YoY)451.36M146.71%

Tarsus Pharmaceuticals Inc (TARS) Earnings History

Release Date	Period End	EPS/Forecast	Revenue/Forecast	EPS Surprise %	Revenue Surprise %
8/6/2026	06/2026	-0.43/-0.20	173.91M/169.68M	-118.12%	2.50%
5/6/2026	03/2026	-0.16/-0.37	162.05M/147.72M	56.22%	9.70%
2/23/2026	12/2025	-0.20/-0.10	151.67M/144.57M	-105.79%	4.91%
11/4/2025	09/2025	-0.30/-0.35	118.70M/115.22M	15.71%	3.02%
8/6/2025	06/2025	-0.48/-0.40	102.66M/95.68M	-20.17%	7.29%
5/1/2025	03/2025	-0.64/-0.73	78.33M/72.47M	12.61%	8.10%
2/25/2025	12/2024	-0.60/-0.74	66.41M/58.33M	19.27%	13.85%
11/13/2024	09/2024	-0.61/-0.97	48.12M/43.44M	37.26%	10.78%

Tarsus Pharmaceuticals Inc Earnings News

Tarsus Q2 2026 earnings: XDEMVY sales rise 69% as spending limits loss improvement

Tarsus Pharmaceuticals’ Q2 2026 results were led by XDEMVY net product sales of $173.9 million, up more than 69% year over year. Basic and diluted net loss per share narrowed to $0.43 from $0.48, but expanded commercialization and clinical-development spending kept the company unprofitable despite higher product volume and improved gross-to-net discounts. Tarsus raised full-year 2026 XDEMVY net product sales guidance to $685 million-$705 million as prescription depth increased, while pipeline expansion and continued investment remain central issues for investors to monitor.

TradingKeyThu, Aug 6

Tarsus Pharmaceuticals Inc